ADVIA CENTAUR HCV READY PACK REAGENTS, ADVIA CENTAUR HCV QUALITY CONTROL MATERIALS

Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus

FDA Premarket Approval P030056

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the advia centaur hcv. Hcv readypack reagents: the advia centaur hcv assay is an in vitro diagnostic immunoassay for the qualitative determination of immunoglobulin g (igg) antibodies to hepatitis c virus (hcv) in human serum and plasma (edta, lithium or sodium heparinized) using the advia centaur system. The assay may be used in conjunction with other serological and clinical information to aid in the diagnosis of individuals with symptoms of hepatitis and in individuals at risk for hepatitis c infection. Hcv quality control materials: for in vitro diagnostic use in monitoring the performance of the hcv assay on the advia centaur systems. The performance of the hcv quality control material has not been established with any other anti-hcv assays.

DeviceADVIA CENTAUR HCV READY PACK REAGENTS, ADVIA CENTAUR HCV QUALITY CONTROL MATERIALS
Classification NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Generic NameAssay, Enzyme Linked Immunosorbent, Hepatitis C Virus
ApplicantSIEMENS HEALTHCARE DIAGNOSTICS
Date Received2003-12-24
Decision Date2004-12-22
Notice Date2005-11-28
PMAP030056
SupplementS
Product CodeMZO
Docket Number05M-0478
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address SIEMENS HEALTHCARE DIAGNOSTICS 333 Coney Street walpole, MA 02032-1516
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P030056Original Filing
S020 2021-04-01 30-day Notice
S019 2020-12-22 Real-time Process
S018 2020-07-31 30-day Notice
S017 2020-05-22 30-day Notice
S016 2020-03-09 30-day Notice
S015 2020-02-21 30-day Notice
S014 2019-02-01 30-day Notice
S013 2018-07-19 Real-time Process
S012
S011 2017-09-29 Normal 180 Day Track
S010 2015-06-11 30-day Notice
S009 2015-05-01 Normal 180 Day Track
S008 2014-09-15 Normal 180 Day Track
S007 2012-03-26 Normal 180 Day Track No User Fee
S006 2009-05-18 Normal 180 Day Track
S005 2009-03-31 Normal 180 Day Track
S004 2009-03-09 Normal 180 Day Track No User Fee
S003 2009-02-04 30-day Notice
S002 2008-08-25 Normal 180 Day Track
S001

NIH GUDID Devices

Device IDPMASupp
00630414597867 P030056 002
00630414473161 P030056 002
00630414278759 P030056 002
00630414278742 P030056 002
00630414301341 P030056 002

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.